| Response Genetics

Skip to Main Content

Search:

Company
ResponseDX™
Products & Services
Our Technology
Investor Relations
CLIA & GLP
News
Contact

Home Feature

Response Genetics PCR-based genetic tests--ResponseDX: Lung™ and ResponseDX: Colon™--provide personalized genetic information that will help guide cancer patients and doctors in choosing the most beneficial treatment options for patients.

To maximize useful pharmacogenomic information derived from clinical trial samples that enables the pharmaceutical industry to move more rapidly towards personalized medicine. In other words: Getting the right therapy to each patient the first time.

Response Genetics Reports Second Quarter 2007 Financial Results, Response Genetics Study to Focus on Developing Diagnostic Test Kits for Pancreatic Cancer

Company | ResponseDX™| Products & Services | Our Technology | Investor Relations | CLIA & GLP | News | Contact